In recent years, there has been an increasing degree of convergence between the fields of health technology and biopharmaceuticals. Decentralized clinical trials are a good example of this trend. But even before the pandemic that led to the rapid expansion of decentralized trials, biopharmaceutical companies had been experimenting with various R&D techniques.
The use of machine learning and other forms of artificial intelligence for drug development is an exciting trend full of possibilities, especially as the technology matures and companies adapt.
AI in drug development is just MedCity INVEST PhrmaTech Virtual meeting, scheduled for Tuesday, July 26.
To view the full agenda, Click here. Registration is free.
The session will explore some of the ways health tech and biopharma intersect, from conversations on digital medicines to virtual clinical trials.
group discussion, The state of artificial intelligence in drug discovery, which will kick off the meeting. Here is a description:
AI in healthcare has finally gone from being over-hyped to showing some practical applications. If it succeeds in drug discovery, it would be a huge achievement that could help speed up and reduce the cost of drug development. Learn from the experts how we are effectively using AI for drug discovery.
host: Frank Vinluan, Senior Biopharmaceutical Reporter, MedCity News
The speaker:
- Chris Gibson, Co-founder and CEO, Recursion
- Richard Law, Chief Commercial Officer, Exscientia
- Sana Mujahid, Senior Scientist, Aria Pharmaceuticals
- Eric Steager, Venture Partner, Touchdown Ventures
A start-up pitch competition will also be held. It will focus on companies that are developing technologies to address innovative approaches to clinical trial design, patient recruitment, remote patient monitoring, and more, all of which have the potential to transform clinical trials.
Judges on Pitch Perfect include:
- Cris De Luca, Digital Partner, Sanofi Ventures
- Jessica Federer, Partner, Boston Millennium Partners
- Joel Krikston, Managing Director of Venture Capital and Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund
- Maxim Owen, Venture Partner, Wavemaker Thirty Sixty Health
Interested in MedCity News sponsorship opportunities at this and other conferences? Please contact MedCity News Publisher Ken Montgomery: kmontgomery@medcitynews.com.
